QUINTA-ANALYTICA, an established Czech provider of R&D and regulatory services for the pharmaceutical, biotechnology and generic drug industries changes ownership. Genesis Private Equity Fund III (GPEF III) from the established private equity group Genesis Capital, sold its 85.9% ownership stake in the Company to LVA Holding GmbH, a portfolio company of BBA Capital Partners (BBA).
After 24 years of development and innovation since its establishment, QUINTA-ANALYTICA successfully completed its transition into a major provider of services to global pharmaceutical players. During the six-year partnership with Genesis Capital, the Company expanded the portfolio of services provided, diversified its client portfolio, and continued to expand not only in Europe but also in North America. In 2021, QUINTA-ANALYTICA is on track to reach revenues of € 16 million with over 200 highly qualified professionals.
The entry of GPEF III into QUINTA-ANALYTICA in 2016 was an example of a successful generational succession. GPEF III acquired the majority stake and started the Company’s growth strategy. Its key element was strengthening of the Company’s management, whose members also became minority shareholders alongside GPEF III.
Jan Tauber, Chairman at Genesis Capital Equity, said: “The investment into QUINTA-ANALYTICA was one of the successful stories in more than two decades of Genesis history. As in most cases of Genesis’ investments, the drivers of this accomplishment were highly motivated and competent employees as well as the top management. Over the six years of Genesis involvement, the management navigated the business safely through challenging times, especially overcoming the negative impact of COVID-19. I am convinced, the Company is currently well positioned and prepared for further growth with the new owner.”
Roman Grunt, the Chairman of the Board of Directors of QUINTA-ANALYTICA, added: “This move is another step for QUINTA and its people on our growth path. Genesis supported our development projects and together we managed to overcome difficult years. I would like to thank the Genesis team for this. We are now looking forward to going ahead with our new partner. We knew this change must come and I am delighted that it is BBA. Today we have a chance to not only keep QUINTA’s essence, but with the network and financial support of our new partner we will grow further and play a leading role in building the pharma division within BBA’s portfolio. I cannot thank our employees and partners enough for where we are today. With this wind in our back, we strive to go further and provide the best possible service to our customers “
Commenting on the acquisition, Felix Burgdorf, Managing Director and Co-Founder of BBA, stated: “QUINTA-ANALYTICA is a leading independent partner for pharmaceutical companies, ensuring pharmaceutical drugs are safely and rapidly brought to those who need them. The Company’s focus on its customers, high quality, scientific excellence, and flexibility differentiates it in the market. We are excited to partner with the top management team and employees to continue to be a reliable partner to QUINTA-ANALYTICA’s customers as well as to sustainably and responsibly develop the Company to the benefit of end-consumers.”
The sellers were advised by HAVEL & PARTNERS on the legal aspects. Buyside was represented by Noerr on the legal side and advised by Ernst & Young on the financial and tax due diligence aspects.
Established in 1997 by team of founders lead by Miroslav Ryska from Research Institute for Pharmacy and Biochemistry. QUINTA-ANALYTICA, based in Prague, is one of the biggest independent companies in Central and Eastern Europe specialising in commercial services for pharmaceutical, biotechnology and generic drug industries. The main domains are pharmacokinetics and BA/BE clinical studies, bioanalytics, drug analysis including method development and transfer, batch quality control release, stability studies, analytics in inhalation antiasthmatics, peptides and proteins. QUINTA-ANALYTICA is regularly inspected by European agencies represented in the Czech Republic by State Institute for Drug Control (SUKL) and has also successfully passed through several audits of the U.S Food and Drug Administration (FDA).
QUINTA-ANALYTICA consists of five divisions: the biggest is the Pharmaceutical Analysis, Clinical Testing, Analytical Testing, Analytical R&D and Biopharma Analyses. The Company also has 2 in-house Clinical Units at its own facility. In 2020 the Company opened a modern innovative laboratory in Brno. QUINTA-ANALYTICA has 200 experienced in-house professionals serving major global players from the pharmaceutical industry.
For more information, please visit: www.quinta.cz
About BBA Capital Partners
BBA is an owner-managed and financed investment company that offers long-term entrepreneurial capital to medium-sized market leaders. In its “Family Equity” philosophy, it combines the long-term, strategic mindset of a family business with sustainable and professional corporate development.
For more information, please visit: www.bba-partners.de
About Genesis Capital
Genesis Capital is a private equity group offering financing for growth and development to small and medium companies in Central Europe. Since its foundation in 1999, Genesis Capital has advised six private equity funds with a total volume exceeding EUR 300 million. These funds have already supported more than 60 companies.
At present, Genesis funds hold investments in the following companies: HP Tronic/Datart, Sanborn, Stangl Technik Holding, 11 Entertainment Group, Summa Linguae Technologies, Conectart and GTH Multicatering.
For more information, please visit: www.genesis.cz/en
PR representation of Genesis Capital:
David Vondra, Insighters
E-mail: firstname.lastname@example.org; Tel.: +420 776 700 131